| 9.83 0 (0.46%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.11  |
1-year : | 16.11 |
| Resists | First : | 12.08 |
Second : | 13.8 |
| Pivot price | 10.88 |
|||
| Supports | First : | 9.31 |
Second : | 7.74 |
| MAs | MA(5) : | 10.55 |
MA(20) : | 11.19 |
| MA(100) : | 13.14  |
MA(250) : | 12.61 |
|
| MACD | MACD : | -1 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 16.4 |
D(3) : | 18.7 |
| RSI | RSI(14): 30.6 | |||
| 52-week | High : | 39.75 | Low : | 6.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PMN ] has closed below the lower bollinger band by 9.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ PMN ] is to continue within current trading range. It is unclear right now based on current values. 71.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.95 - 10.01 | 10.01 - 10.07 |
| Low: | 9.17 - 9.24 | 9.24 - 9.31 |
| Close: | 9.72 - 9.83 | 9.83 - 9.93 |
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Wed, 15 Apr 2026
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
Thu, 09 Apr 2026
Major holders and board changes in ProMIS Neurosciences (PMN) 2026 proxy statement - Stock Titan
Fri, 27 Feb 2026
PMN Stock Price and Chart — NASDAQ:PMN - TradingView
Mon, 23 Feb 2026
Insider Buying: Johanne Kaplan Acquires Shares of ProMIS Neurosc - GuruFocus
Fri, 30 Jan 2026
ProMIS Neurosciences stock soars after $175 million private placement - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 20.4 (%) |
| Held by Institutions | 32.7 (%) |
| Shares Short | 138 (K) |
| Shares Short P.Month | 135 (K) |
| EPS | -22.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -176.5 % |
| Return on Equity (ttm) | -521.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.73 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.44 |
| PEG Ratio | 0 |
| Price to Book value | -16.95 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|